Bayer Group Key Data

 

 

Q2 2016

Q2 2017

 

Change

 

H1 2016

H1 2017

 

Change

 

Full Year 2016

 

 

€ million

€ million

 

%

 

€ million

€ million

 

%

 

€ million

2016 figures restated

1

For definition see Annual Report 2016, Chapter “Alternative Performance Measures Used by the Bayer Group.”

2

Employees calculated as full-time equivalents (FTEs)

Sales

 

11,833

12,193

 

+3.0

 

23,687

25,437

 

+7.4

 

46,769

Change (adjusted for currency and portfolio effects)1

 

 

 

 

+1.9

 

 

 

 

+5.7

 

+3.5%

Change in sales1

 

 

 

 

 

 

 

 

 

 

 

 

Volume

 

+4.4%

−1.9%

 

 

 

+4.8%

+2.0%

 

 

 

+4.2%

Price

 

−2.1%

+3.8%

 

 

 

−2.0%

+3.7%

 

 

 

−0.7%

Currency

 

−3.8%

+1.0%

 

 

 

−3.3%

+1.7%

 

 

 

−2.0%

Portfolio

 

+0.1%

+0.1%

 

 

 

0.0%

0.0%

 

 

 

0.0%

EBITDA1

 

2,952

2,983

 

+1.1

 

6,311

6,829

 

+8.2

 

10,785

Special items1

 

(102)

(73)

 

 

 

(130)

(120)

 

 

 

(517)

EBITDA before special items1

 

3,054

3,056

 

+0.1

 

6,441

6,949

 

+7.9

 

11,302

EBITDA margin before special items1

 

25.8%

25.1%

 

 

 

27.2%

27.3%

 

 

 

24.2%

EBIT1

 

2,138

2,151

 

+0.6

 

4,458

5,267

 

+18.1

 

7,042

Special items1

 

(104)

(205)

 

 

 

(376)

(290)

 

 

 

(1,088)

EBIT before special items1

 

2,242

2,356

 

+5.1

 

4,834

5,557

 

+15.0

 

8,130

Financial result

 

(314)

(405)

 

−29.0

 

(629)

(754)

 

−19.9

 

(1,155)

Net income (from continuing and discontinued operations)

 

1,380

1,224

 

−11.3

 

2,891

3,307

 

+14.4

 

4,531

Earnings per share (from continuing and discontinued operations) (€)1

 

1.67

1.40

 

−16.2

 

3.50

3.79

 

+8.3

 

5.44

Core earnings per share (from continuing operations) (€)1

 

2.07

1.81

 

−12.6

 

4.42

4.44

 

+0.5

 

7.32

Net cash provided by operating activities (from continuing and discontinued operations)

 

1,982

2,313

 

+16.7

 

3,304

3,154

 

−4.5

 

9,089

Cash outflows for capital expenditures

 

589

476

 

−19.2

 

952

891

 

−6.4

 

2,578

Research and development expenses

 

1,122

1,165

 

+3.8

 

2,231

2,323

 

+4.1

 

4,666

Depreciation, amortization and impairments

 

814

832

 

+2.2

 

1,853

1,562

 

−15.7

 

3,743

Number of employees at end of period2

 

115,576

115,680

 

+0.1

 

115,576

115,680

 

+0.1

 

115,200

Personnel expenses (including pension expenses)

 

2,789

2,826

 

+1.3

 

5,621

5,950

 

+5.9

 

11,357